The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
THE CARDIAC FIBROBLAST: Therapeutic Target in Myocardial Remodeling and Failure
Abstract
▪ Abstract Cardiac fibroblasts play a central role in the maintenance of extracellular matrix in the normal heart and as mediators of inflammatory and fibrotic myocardial remodeling in the injured and failing heart. In this review, we evaluate the cardiac fibroblast as a therapeutic target in heart disease. Unique features of cardiac fibroblast cell biology are discussed in relation to normal and pathophysiological cardiac function. The contribution of cardiac fibrosis as an independent risk factor in the outcome of heart failure is considered. Candidate drug therapies that derive benefit from actions on cardiac fibroblasts are summarized, including inhibitors of angiotensin-aldosterone systems, endothelin receptor antagonists, statins, anticytokine therapies, matrix metalloproteinase inhibitors, and novel antifibrotic/anti-inflammatory agents. These findings point the way to future challenges in cardiac fibroblast biology and pharmacotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F. M., Moye, L. A., Goldman, S., Flaker, G. C., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.9.839 · Cited by 1,389
Ziesche, R., Hofbauer, E., Wittmann, K., Petkov, V., & Block, L.-H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910213411703 · Cited by 586
Isoprenoids as mediators of the biological effects of statins
Liao, J. K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216421 · Cited by 352
Diep, Q. (2004) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2003.11.004 · Cited by 165
Nwogu, J. I., Geenen, D., Bean, M., Brenner, M. C., Huang, X., & Buttrick, P. M. (2001) · Circulation · doi:10.1161/hc4301.097193 · Cited by 131
Cited by
Hinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M.-L., & Gabbiani, G. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070112 · Cited by 2,068
Formation and function of the myofibroblast during tissue repair
Hinz, B. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700613 · Cited by 1,658
Frangogiannis, N. G. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa324 · Cited by 1,229
Stromal myofibroblasts are drivers of invasive cancer growth
De Wever, O., Demetter, P., Mareel, M., & Bracke, M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23925 · Cited by 722
The myofibroblast: Paradigm for a mechanically active cell
Hinz, B. (2010) · Journal of Biomechanics · doi:10.1016/j.jbiomech.2009.09.020 · Cited by 698
Metadata
- Authors
- Brown, R. D., Ambler, S. K., Mitchell, M. D., & Long, C. S.
- Venue
- Annual Review of Pharmacology and Toxicology
- Publisher
- Annual Reviews
- Published
- 2005-09-22
- Volume
- 45
- Issue
- 1
- Pages
- 657-687
- ISSN
- 0362-1642 (ISSN-L)
- 1545-4304
- OpenAlex
- W2129328611
- Cited by
- 647
- References
- 9
- FWCI
- 3.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: THE CARDIAC FIBROBLAST: Therapeutic Target in Myocardial Remodeling and Failure. https://app.cochat.ai/papers/10.1146/annurev.pharmtox.45.120403.095802
- The paper
- Brown, R. D., Ambler, S. K., Mitchell, M. D., & Long, C. S. (2005). THE CARDIAC FIBROBLAST: Therapeutic Target in Myocardial Remodeling and Failure. Annual Review of Pharmacology and Toxicology. https://doi.org/10.1146/annurev.pharmtox.45.120403.095802
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
